84 related articles for article (PubMed ID: 1760831)
1. Sustained-release IS-5-MN in the treatment of coronary heart disease.
Keck M
Cardiology; 1991; 79 Suppl 2():51-7. PubMed ID: 1760831
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris.
Krepp HP
Cardiology; 1991; 79 Suppl 2():14-8. PubMed ID: 1760823
[TBL] [Abstract][Full Text] [Related]
3. Antianginal efficacy and tolerability of 50 mg sustained-release isosorbide 5-mononitrate in an open twelve-month observation study.
Heepe W; Gathmann-Lewik U
Cardiology; 1987; 74 Suppl 1():34-9. PubMed ID: 3111689
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischemic episodes.
Friedensohn A; Meshulam R; Schlesinger Z
Cardiology; 1991; 79 Suppl 2():31-40. PubMed ID: 1760827
[TBL] [Abstract][Full Text] [Related]
5. [Intraindividual dose-response relationship of sustained-release Elantan].
Kenedi P
Z Kardiol; 1986; 75 Suppl 3():77-9. PubMed ID: 3541420
[TBL] [Abstract][Full Text] [Related]
6. [4 different nitrate preparations with regard to the possible development of tolerance in long-term treatment].
Mertens HM; Ohlmeier H; Mannebach H; Kabelitz K; Gleichmann U
Herz; 1985 Jun; 10(3):172-81. PubMed ID: 3926614
[TBL] [Abstract][Full Text] [Related]
7. Slow-release isosorbide-5-mononitrate--a new once daily therapeutic modality for angina pectoris.
Ahmadinejad M; Eghbal B; Sorgenicht W; Schneeweiss A; Weiss M
Eur Heart J; 1988 Jan; 9 Suppl A():135-9. PubMed ID: 3137063
[TBL] [Abstract][Full Text] [Related]
8. [Anti-ischemic efficacy of sustained-release isosorbide-5-mononitrate: echocardiography during mental and physical stress].
Keck M; Tretter R; Sauerbrey-Wullkopf N
Z Kardiol; 2001 Oct; 90(10):766-73. PubMed ID: 11757473
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris.
Parker JO; Baird MG
Can J Cardiol; 1994 Nov; 10(9):909-12. PubMed ID: 7954026
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
Neuhaus R; Johnen R; Vydra L; Solbach C
Pharmatherapeutica; 1986; 4(8):486-95. PubMed ID: 3086899
[TBL] [Abstract][Full Text] [Related]
11. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker JO
Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
[TBL] [Abstract][Full Text] [Related]
12. [Extent of therapeutic effect and duration of 1 capsule of 120 mg isosorbide dinitrate in a slow release form].
Vogler AC; Silber S; Spiegelsberger F; Theisen K
Z Kardiol; 1989 Jul; 78(7):421-6. PubMed ID: 2672652
[TBL] [Abstract][Full Text] [Related]
13. Influence of isosorbide 5-mononitrate 20 mg, sustained-release 50 mg and sustained-release nifedipine 20 mg on ischaemic ST-segment changes during Holter monitoring. A double-blind cross-over study in patients with spontaneous angina pectoris.
von Arnim T
Cardiology; 1987; 74 Suppl 1():40-5. PubMed ID: 3300977
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and duration of action of isosorbide-5-mononitrate in the treatment of stable angina of effort. Comparison with sustained-release isosorbide dinitrate].
Lagioia R; Scrutinio D; Mangini SG; De Toma L; Accettura D; De Nicolò M; Saliani P; Preziusi N; Antuofermo F; Rizzon P
G Ital Cardiol; 1985 Mar; 15(3):299-306. PubMed ID: 4018470
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy.
Mitrovic V; Gessner C; Hain P; Müller KD; Schlepper M
Clin Cardiol; 1991 Mar; 14(3):209-18. PubMed ID: 1672843
[TBL] [Abstract][Full Text] [Related]
16. Isosorbide-5-mononitrate and nifedipine can reduce ischaemic ST-segment changes during Holter monitoring in patients with spontaneous angina pectoris.
von Arnim T; Erath A; Reuschel-Janetschek E
Eur Heart J; 1988 Jan; 9 Suppl A():113-8. PubMed ID: 3409907
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relation of antianginal activity of isosorbide dinitrate.
Schneider WU; Bussmann WD; Stahl B; Kaltenbach M
Am J Cardiol; 1984 Mar; 53(6):700-5. PubMed ID: 6702616
[TBL] [Abstract][Full Text] [Related]
18. Effect of a combination of pindolol and isosorbide dinitrate on ischemic ST-segment depression and exercise ability in angina pectoris.
Dorow P; Schiess W
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):419-22. PubMed ID: 6386704
[TBL] [Abstract][Full Text] [Related]
19. Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil.
Stauch M; Grossmann G; Wanjura D; Adam WE
Eur J Clin Pharmacol; 1990; 38 Suppl 1():S31-4. PubMed ID: 2354712
[TBL] [Abstract][Full Text] [Related]
20. Slow release isosorbide-5-mononitrate therapy in angina pectoris. Effects of exercise performance and hemodynamics.
Jansen W; Prenzel R; Rappert B; Kümper H; Laufen H; Tauchert M
Cardiology; 1991; 79 Suppl 2():78-85. PubMed ID: 1760835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
